Skip to main
QURE
QURE logo

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 41%
Buy 45%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV demonstrated strong financial growth in 2024, reporting revenues of $27.1 million, representing a significant 71% year-over-year increase, primarily driven by licensing and collaboration revenues despite a decline in contract manufacturing revenue. The company's probability of success for its Huntington's disease gene therapy, AMT-130, has been significantly upgraded to 75%, with expectations for a commercial launch by 2026, bolstered by positive feedback from the FDA. Additionally, the estimated gross pricing for AMT-130 has been increased to $2.5 million, reflecting a strong outlook for the therapy amid positive advancements in regulatory discussions and anticipated approval pathways.

Bears say

The analysis indicates a negative outlook on uniQure NV due to a significant downturn in revenue estimates, now projected to peak at over $2 billion, suggesting diminishing market confidence in its growth trajectory. Additionally, substantial reductions in R&D and SG&A expenses—33% and 29% year-over-year, respectively—reflect serious operational cutbacks, including a drastic workforce reduction and facility sale, which may hinder innovation and long-term sustainability. Despite a cash runway extending into the second half of 2027, concerns about the company's clinical pipeline momentum and the reliability of diagnostic markers raise questions about the overall viability and potential success of its therapeutic developments, particularly in Huntington's disease.

uniQure (QURE) has been analyzed by 29 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 45% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 29 analysts, uniQure (QURE) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.